K Pharma (4896) · RiskRestated
Obsolescence of Research and Development Activities Due to Rapid Technological Innovation
First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Risk of existing services becoming obsolete, losing competitiveness and incurring investment burdens due to delays in responding to rapid technological innovationA theme 459 companies write about · 471 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2026: 34 of 95 companies on the "Worse" side.
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 194 companies compared. The sentences above are computed from all 194.Comparing 200 of the theme's 471 threads.Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「We operate in the biotechnology sector, where technological innovation and progress are particularly rapid.」
The company reiterates the risks of falling behind rapid technological innovation, obsolescence of research and development and additional costs. - FY2024RestatedAnnual report
「We operate in the biotechnology sector, where technological innovation and progress are particularly rapid.」
The company reiterates the risks of falling behind rapid technological innovation, obsolescence of research and development and additional costs. - FY2023First statedAnnual report
「If we are unable to keep pace with rapid technological innovation and progress, or if our research and development becomes obsolete,」
The company identifies the risk that rapid advances in biotechnology may make its research and development obsolete or require additional costs to respond.